In Ohio, the Cleveland Clinic joined the Circulating Cell-free Genome Atlas, a national clinical trial that is looking for 7,000 cancer patients and 3,000 healthy patients in the U.S. Their goal is to analyze DNA and RNA in the blood and build a database that will help with detecting cancer early on when it is easier to cure. Researchers believe that using genome sequencing from blood samples could possibly replace x-rays for early cancer detection. Funded by a company in California, GRAIL, Inc., the project will be looking for molecule patterns in the blood for specific types of cancers.
Latest article
You better be-leaf it: Dawn Bio cultivates wood in a petri dish
In the Netherlands, a startup based at Wageningen University’s campus is pioneering technology to produce wood from cultured cells.
Dubbed Dawn Bio, the company has...
Algae-based snowboards from WNDR get nod from Time Magazine
In Utah, WNDR Alpine’s algae-based snowboards have been named to Time Magazine’s top 200 inventions list.
Unlike most snowboards, which are made out of petroleum-based...
Prince William’s Earthshot Prize names seaweed firm Coast 4C as a finalist
In Australia, a startup sustainably cultivating seaweed has been chosen as a finalist for Prince William’s 2024 Earthshot Prize.
Coast 4C works with farmers in...